Kidney Transplant Noninferior From Donors With Versus Without HIV in HIV-Positive Recipients
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 17, 2024 -- Among recipients with HIV, kidney transplantation from donors with HIV is noninferior to that from donors without HIV, according to a study published online Oct. 16 in the New England Journal of Medicine.
Christine M. Durand, M.D., from Johns Hopkins University School of Medicine in Baltimore, and colleagues compared transplantation of kidneys from deceased donors with and without HIV to recipients with HIV. The primary outcome was a safety event (composite of death from any cause, graft loss, serious adverse events, HIV breakthrough event, persistent failure of HIV treatment, or opportunistic infection), assessed for noninferiority.
The researchers enrolled 408 transplantation candidates: 198 received a kidney from a deceased donor, including 99 from a donor with and 99 from a donor without HIV. The adjusted hazard ratio for the composite primary outcome was 1.00 (95 percent confidence interval, 0.73 to 1.38), which demonstrated noninferiority. Overall survival at one and three years, survival without graft loss at one and three years, and rejection at one and three years were similar whether or not the donor had HIV. The groups had a similar incidence of serious adverse events, infections, surgical or vascular complications, and cancer. Recipients of kidneys from donors with HIV had an increased incidence of HIV breakthrough infection (incidence rate ratio, 3.14).
"This multicenter, observational study showed that kidney transplantation from donors with HIV to recipients with HIV is noninferior to kidney transplantation from donors without HIV to recipients with HIV," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Cell Therapy MDR-101 Produces Functional Immune Tolerance in Kidney Transplant Recipients
TUESDAY, July 15, 2025 -- Kidney transplant recipients receiving the investigational cellular product MDR-101 achieved functional immune tolerance for more than two years...
FDA Approves Twice-Yearly Yeztugo for Preexposure Prophylaxis to Cut HIV Risk
FRIDAY, June 20, 2025 -- The U.S. Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to...
Anal Cancer Screening Cost-Effective for HIV+ Men Who Have Sex With Men ≥35 Years of Age
TUESDAY, June 17, 2025 -- For men who have sex with men (MSM) with HIV, aged 35 years or older, anal cancer screening is cost-effective, according to a study published online June...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.